1. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Clinical and Hypoxemic Childhood Pneumonia over Three Years in Central Malawi: An Observational Study.
- Author
-
Eric D McCollum, Bejoy Nambiar, Rashid Deula, Beatiwel Zadutsa, Austin Bondo, Carina King, James Beard, Harry Liyaya, Limangeni Mankhambo, Marzia Lazzerini, Charles Makwenda, Gibson Masache, Naor Bar-Zeev, Peter N Kazembe, Charles Mwansambo, Norman Lufesi, Anthony Costello, Ben Armstrong, and Tim Colbourn
- Subjects
Medicine ,Science - Abstract
The pneumococcal conjugate vaccine's (PCV) impact on childhood pneumonia during programmatic conditions in Africa is poorly understood. Following PCV13 introduction in Malawi in November 2011, we evaluated the case burden and rates of childhood pneumonia.Between January 1, 2012-June 30, 2014 we conducted active pneumonia surveillance in children 75% three-dose PCV13 coverage (post). We also used multivariable time-series regression, adjusting for autocorrelation and exploring seasonal variation and alternative model specifications in sensitivity analyses. The early versus post analysis showed an increase in cases and rates of total, fast breathing, and indrawing pneumonia and a decrease in danger sign and hypoxemic pneumonia, and pneumonia mortality. At 76% three-dose PCV13 coverage, versus 0%, the time-series model showed a non-significant increase in total cases (+47%, 95% CI: -13%, +149%, p = 0.154); fast breathing cases increased 135% (+39%, +297%, p = 0.001), however, hypoxemia fell 47% (-5%, -70%, p = 0.031) and hospital deaths decreased 36% (-1%, -58%, p = 0.047) in children
- Published
- 2017
- Full Text
- View/download PDF